4D Pharma PLC Annual Report and Notice of AGM

A study that compared women with and without fibromyalgia has, for the first time, linked gut bacteria to the long-lasting disease and its main symptoms. Researchers in Canada identified 19 species of gut bacteria that were

Fibromyalgia affects 2-4 percent of the population and has no known cure. Symptoms include fatigue, impaired sleep, and cognitive difficulties, but the disease is most clearly characterized by widespread chronic pain. As reported in the journal Pain,

The microbiome plays a vital role in health. A recent study has investigated how viruses that kill gut bacteria influence these microbes. The findings make an already complicated picture much more so. The microbiome is both

4D pharma plc today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be presented by the Lead Investigator, Richard Hansen, Consultant Paediatric Gastroenterologist, Royal Hospital for

Have you ever wonder why a drug that works for someone else doesn’t seem to work for you? It is still a quite mystery for scientists also why certain drugs work well in some people and

4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announced the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid

We share our bodies with trillions of microbes that are critical to staying healthy, but now scientists are getting a much-needed close look at how those bugs can get out of whack and spur disease. One

According to the latest market report published by Persistence Market Research, titled ‘Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 – 2025’, the global microbiome therapeutics marketis expected to exhibit an exponential CAGR of

4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, has today announced that David Norwood, Duncan Peyton and Alex Stevenson have purchased ordinary shares in the Company as listed below. Following this transaction,

4D pharma plc (LON: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today announced the final results for the Group for the year ended 31 December 2018. David Norwood, Chairman of 4D pharma,

Could the final frontier of medicine actually be inside us already? New research like that presented at the recent Gut Microbiota for Health World Summit, organised in part by the American Gastroenterological Society (AGA), is illuminating

4D pharma plc (LON: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be

E171 is a food additive that manufacturers use to whiten various products, including chewing gum, cake icing, and candy, for instance. While the addition of this substance may render certain products more appealing, there is an

4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the Neuro4D conference, Frankfurt, Germany, 13-14 May, 2019. Alex Stevenson, 4D’s Chief Scientific Officer, commented, “We are

Irritable bowel syndrome, or IBS, is one of those health conditions that can be difficult to talk about. And when you are struggling with things like diarrhea, constipation, gas, and bloating, it’s completely understandable. But there

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the inaugural Chardan Capital Markets LLC Microbiome Medicines Summit. Alex Stevenson, 4D’s Chief Scientific Officer, gave a